Korting HC - Search Results

1

Different skin thinning potential of equipotent medium-strength glucocorticoids.

Korting HC, Unholzer A, Schäfer-Korting M, Tausch I, Gassmueller J, Nietsch KH. Korting HC, et al. Skin Pharmacol Appl Skin Physiol. 2002 Mar-Apr;15(2):85-91. doi: 10.1159/000049394. Skin Pharmacol Appl Skin Physiol. 2002. PMID: 11867964 Clinical Trial.

2

Skin penetration and metabolism of topical glucocorticoids in reconstructed epidermis and in excised human skin.

Gysler A, Kleuser B, Sippl W, Lange K, Korting HC, Höltje HD, Korting HC. Gysler A, et al. Among authors: korting hc. Pharm Res. 1999 Sep;16(9):1386-91. doi: 10.1023/a:1018946924585. Pharm Res. 1999. PMID: 10496654

3

Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts.

Gysler A, Lange K, Korting HC, Schäfer-Korting M. Gysler A, et al. Among authors: korting hc. Pharm Res. 1997 Jun;14(6):793-7. doi: 10.1023/a:1012162708675. Pharm Res. 1997. PMID: 9210199

4

Differential effect of medium potent nonhalogenated double-ester-type and conventional glucocorticoids on proliferation and chemotaxis of fibroblasts in vitro.

Hein R, Korting HC, Mehring T. Hein R, et al. Among authors: korting hc. Skin Pharmacol. 1994;7(5):300-6. doi: 10.1159/000211309. Skin Pharmacol. 1994. PMID: 8054213

5

Topical glucocorticoids with improved risk-benefit ratio. Rationale of a new concept.

Schäfer-Korting M, Schmid MH, Korting HC. Schäfer-Korting M, et al. Among authors: korting hc. Drug Saf. 1996 Jun;14(6):375-85. doi: 10.2165/00002018-199614060-00003. Drug Saf. 1996. PMID: 8828015 Review.

6

Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids.

Schäfer-Korting M, Korting HC, Kerscher MJ, Lenhard S. Schäfer-Korting M, et al. Among authors: korting hc. Clin Pharmacol Ther. 1993 Oct;54(4):448-56. doi: 10.1038/clpt.1993.172. Clin Pharmacol Ther. 1993. PMID: 8222488 Clinical Trial.

7

Comparative efficacy and safety of bifonazole 1% cream and the corresponding base preparation in the treatment of seborrhoeic dermatitis.

Zienicke H, Korting HC, Braun-Falco O, Effendy I, Hagedorn M, Küchmeister B, Meisel C. Zienicke H, et al. Among authors: korting hc. Mycoses. 1993 Sep-Oct;36(9-10):325-31. doi: 10.1111/j.1439-0507.1993.tb00776.x. Mycoses. 1993. PMID: 8015566 Clinical Trial.

8

Innovative agents for actinic keratosis and nanocarriers enhancing skin penetration.

Schäfer-Korting M, Höltje M, Korting HC, Höltje HD. Schäfer-Korting M, et al. Among authors: korting hc. Skin Pharmacol Physiol. 2010;23(1):6-14. doi: 10.1159/000257258. Epub 2010 Jan 14. Skin Pharmacol Physiol. 2010. PMID: 20090403

9

Glucocorticoids for human skin: new aspects of the mechanism of action.

Schafer-Korting M, Kleuser B, Ahmed M, Holtje HD, Korting HC. Schafer-Korting M, et al. Among authors: korting hc. Skin Pharmacol Physiol. 2005 May-Jun;18(3):103-14. doi: 10.1159/000084907. Skin Pharmacol Physiol. 2005. PMID: 15897682 Review.

10

Glucocorticoid entrapment into lipid carriers--characterisation by parelectric spectroscopy and influence on dermal uptake.

Sivaramakrishnan R, Nakamura C, Mehnert W, Korting HC, Kramer KD, Schäfer-Korting M. Sivaramakrishnan R, et al. Among authors: korting hc. J Control Release. 2004 Jul 7;97(3):493-502. doi: 10.1016/j.jconrel.2004.04.001. J Control Release. 2004. PMID: 15212881

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results